Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from Amgen, Inc. publish findings in breast cancer
June 26th, 2008
"Bone metastases cause severe skeletal morbidity including fractures and hypercalcemia. Tumor cells in bone induce activation of osteoclasts, which mediate bone resorption and release of growth factors from bone matrix, resulting in a ''vicious cycle'' of bone breakdown and tumor proliferation," scientists in the United States report. "Receptor activator of NF-kappa B ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival, and is blocked by a soluble decoy receptor, osteoprotegerin (OPG). In human malignancies that metastasize to bone, dysregulation of the RANK/ RANKL/OPG pathway can increase the RANKL: OPG ratio, a condition which...
Source: Women's Health Weekly (2008-06-26)
|
